Definium Therapeutics edges out Compass Pathways on peak potential, though both have good management and unique psychedelic drugs. Compass's lead indication, treatment-resistant depression, and Definium's, generalized anxiety disorder, are each about $1.5 billion opportunities, and both target PTSD. Definium also has strong MDD data, adding a $2-3 billion indication. Its LSD session lasts only about six hours, not the 12 hours critics cite. x.com  x.com 

Eli Lilly's acquisition of ATAI further validates the psychedelic therapy thesis behind DFTX and Compass Pathways. The working view is that these companies' trials are slam dunks: humans have known about psychedelics' efficacy for thousands of years, and clinical data is finally catching up. These companies could help millions of people. For DFTX, an acquisition would be unwelcome because it would cap the upside. x.com  x.com 

AbbVie's terminal value is a concern: it has had big autoimmune hits to backfill Humira, yet it still trades at 19x forward earnings on a $450B market cap, while Johnson & Johnson's 2024-25 acquisition spree is paying off. x.com 

Eli Lilly using its GLP-1 cash to buy a psychedelics company is a welcome move. x.com 

Eli Lilly is priced for perfection, but it just might be perfection. A new Nvidia partnership builds lab infrastructure on the BioNeMo platform and Vera Rubin accelerators, using robotics and physical AI to superscale drug discovery and production. Lilly is rumored to be acquiring Insilico Medicine, one of the best AI biology platforms, and retatrutide is delivering outstanding weight loss in the clinic. x.com 

Definium Therapeutics has turned from a high-risk bet into a much safer biotech investment after its single-dose DT120 cleared phase 3 in three of four major trials, all headed to the FDA together. Success in the fourth looks priced in, so full FDA approval is the next catalyst, plus possible Trump administration psychedelics moves. Analyst targets of $70-90 could be reached with commercialization in a couple of years, though more multibaggers are unlikely. Support should hold near $35. x.com 

Abivax's risk-reward still makes a ton of sense because buyout comps point to a large premium. @seedy19tron's analysis suggests a 105% premium to the current price, about $218 a share or roughly $20 billion, would get a deal over the line for Pfizer, Lilly, Takeda, AbbVie or AstraZeneca. x.com 

Small- and mid-cap biotech looks like one of healthcare's more asymmetric setups after a four-year bear market, as AI speeds drug discovery and Big Pharma faces a patent cliff. Over $300B of pharma revenue goes off patent in the next few years, M&A is already ramping hard as pharma hunts for assets, and many small and mid-cap names still trade at reasonable valuations, making them potential takeover targets. x.com 

Big pharma's push into psychedelics, with Eli Lilly buying Atai Life Sciences after AbbVie's deal, is positive for Helus Pharma, the only other company identified with new-chemical-entity patent protection in the field. Helus looks about two years ahead of Atai, with stronger treatment-resistant depression data, at a fraction of its valuation. Its drawback is two dosing sessions of 3-4 hours each versus Atai's single 90-minute visit, so it stays a higher-risk holding. x.com 

Alexandria Real Estate Equities is priced for permanent impairment of irreplaceable life science infrastructure. Its labs in Boston, San Diego and the Bay Area serve biotech and pharma demand that pauses and then snaps back. Biotech venture funding is stabilizing, IPO windows are reopening and Big Pharma has billions for M&A, which flows to Alexandria. New lab construction has slowed sharply, tightening supply into 2026-2027, and the stock trades at a steep discount to replacement cost. x.com